Aldosterone Blockade in CKD: Emphasis on Pharmacology

Advances in Chronic Kidney Disease

Volumn 22, Issue 2, 2015, Pages 123-132

  Schwenk, Michael H ^a   Hirsch, Jamie S ^a   Bomback, Andrew S ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Chronic kidney failure; Hyperkalemia; Mineralocorticoid receptor antagonists; Pharmacokinetics; Proteinuria

Indexed keywords

ALDOSTERONE; CREATININE; EPLERENONE; LISINOPRIL; LOSARTAN; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; BLOOD PRESSURE REGULATION; CAUCASIAN; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; HEART FAILURE; HUMAN; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BIOAVAILABILITY; BLOOD; DRUG EFFECTS; FIBROSIS; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HYPERKALEMIA; INFLAMMATION; KIDNEY FAILURE, CHRONIC; METABOLISM; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL AVAILABILITY; FIBROSIS; GLOMERULAR FILTRATION RATE; GYNECOMASTIA; HUMANS; HYPERKALEMIA; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84923849534     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.08.003     Document Type: Review

References (86)

1. Brilla C.G., Weber K.T. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120(6):893-901.
2. Brilla C.G., Matsubara L.S., Weber K.T. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993, 25(5):563-575.
3. Greene E.L., Kren S., Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98(4):1063-1068.
4. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998, 31(1 Pt 2):451-458.
5. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283(5):H1802-H1810.
6. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A.G., Polly M.L., McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003, 63(5):1791-1800.
7. Sato A., Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 2004, 27(5):303-310.
8. Joffe H.V., Adler G.K. Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005, 10(1):31-37.
9. Fullerton M.J., Funder J.W. Aldosterone and cardiac fibrosis: invitro studies. Cardiovasc Res 1994, 28(12):1863-1867.
10. Rocha R., Stier C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000, 141(10):3871-3878.
11. Rocha R., Chander P.N., Zuckerman A., Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999, 33(1 Pt 2):232-237.
12. Hollenberg N.K. Aldosterone in the development and progression of renal injury. Kidney Int 2004, 66(1):1-9.
13. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 2001, 345(23):1689-1697.
14. Berl T., Katz F.H., Henrich W.L., de Torrente A., Schrier R.W. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int 1978, 14(3):228-235.
15. Hené R.J., Boer P., Koomans H.A., Mees E.J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982, 21(1):98-101.
16. Reams G.P., Bauer J.H. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986, 146(11):2145-2148.
17. Bomback A.S., Klemmer P.J. Mineralocorticoid receptor blockade in chronic kidney disease. Blood Purif 2012, 33(1-3):119-124.
18. Goodfriend T.L., Egan B.M., Kelley D.E. Aldosterone in obesity. Endocr Res 1998, 24(3-4):789-796.
19. Bomback A.S., Klemmer P.J. Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review. Am J Nephrol 2009, 30(2):140-146.
20. Sarzani R., Guerra F., Mancinelli L., Buglioni A., Franchi E., Dessì-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens 2012, 25(7):818-826.
21. Bomback A.S., Kshirsagar A.V., Ferris M.E., Klemmer P.J. Disordered aldosterone-volume relationship in end-stage kidney disease. J Renin Angiotensin Aldosterone Syst 2009, 10(4):230-236.
22. Schrier R.W., Masoumi A., Elhassan E. Aldosterone: role in edematous disorders, hypertension, chronic renal failure, and metabolic syndrome. Clin J Am Soc Nephrol 2010, 5(6):1132-1140.
23. Hung S.-C., Lin Y.-P., Huang H.-L., Pu H.-F., Tarng D.-C. Aldosterone and mortality in hemodialysis patients: role of volume overload. PLoS One 2013, 8(2):e57511.
24. Volk M.J., Bomback A.S., Klemmer P.J. Mineralocorticoid receptor blockade in chronic kidney disease. Curr Hypertens Rep 2011, 13(4):282-288.
25. Klemmer P.J., Bomback A.S. Extracellular volume and aldosterone interaction in chronic kidney disease. Blood Purif 2009, 27(1):92-98.
26. Ando K., Ohtsu H., Arakawa Y., et al. Rationale and design of the Eplerenone Combination versus Conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment Effect (EVALUATE) trial: a double-blinded randomized placebo-controlled trial to evaluate the antialbuminuric effects of an aldosterone blocker in hypertensive patients with albuminuria. Hypertens Res 2010, 33(6):616-621.
27. Fujisawa G., Okada K., Muto S., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004, 66(4):1493-1502.
28. Kawarazaki H., Ando K., Fujita M., et al. Mineralocorticoid receptor activation: a major contributor to salt-induced renal injury and hypertension in young rats. Am J Physiol Ren Physiol 2011, 300(6):F1402-F1409.
29. Kawarazaki W., Nagase M., Yoshida S., et al. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 2012, 23(6):997-1007.
30. Nagase M., Fujita T. Mineralocorticoid receptor activation in obesity hypertension. Hypertens Res 2009, 32(8):649-657.
31. Shibata S., Mu S., Kawarazaki H., et al. Rac1 GTPase in rodent kidneys is essential for salt-sensitive hypertension via a mineralocorticoid receptor-dependent pathway. J Clin Invest 2011, 121(8):3233-3243.
32. Shibata S., Nagase M., Yoshida S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 2008, 14(12):1370-1376.
33. Vogt L., Waanders F., Boomsma F., de Zeeuw D., Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008, 19(5):999-1007.
34. Krikken J.A., Laverman G.D., Navis G. Benefits of dietary sodium restriction in the management of chronic kidney disease. Curr Opin Nephrol Hypertens 2009, 18(6):531-538.
35. Staessen J., Lijnen P., Fagard R., Verschueren L.J., Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981, 91(3):457-465.
36. Biollaz J., Brunner H.R., Gavras I., Waeber B., Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982, 4(6):966-972.
37. McKelvie R.S., Yusuf S., Pericak D., et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999, 100(10):1056-1064.
38. Schjoedt K.J., Andersen S., Rossing P., Tarnow L., Parving H.H. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 2004, 47(11):1936-1939.
39. Cicoira M., Zanolla L., Rossi A., et al. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001, 37(7):1808-1812.
40. MacFadyen R.J., Lee A.F., Morton J.J., Pringle S.D., Struthers A.D. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?. Heart 1999, 82(1):57-61.
41. Persson F., Lewis J.B., Lewis E.J., Rossing P., Hollenberg N.K., Hans-Henrik P. Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy. J Renin Angiotensin Aldosterone Syst 2012, 13(1):118-121.
42. Bomback A.S., Rekhtman Y., Klemmer P.J., Canetta P.A., Radhakrishnan J., Appel G.B. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens 2012, 6(5):338-345.
43. Navaneethan S.D., Nigwekar S.U., Sehgal A.R., Strippoli G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009, 4(3):542-551.
44. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51(2):199-211.
45. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20(12):2641-2650.
46. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006, 1(5):940-951.
47. Esteghamati A., Noshad S., Jarrah S., Mousavizadeh M., Khoee S.H., Nakhjavani M. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial. Nephrol Dial Transpl 2013, 28(11):2823-2833.
48. Bianchi S., Bigazzi R., Campese V.M. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases. Am J Kidney Dis 2010, 55(4):671-681.
49. Furumatsu Y., Nagasawa Y., Tomida K., et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008, 31(1):59-67.
50. Schepkens H., Vanholder R., Billiouw J.M., Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001, 110(6):438-441.
51. Blaustein D.A., Babu K., Reddy A., Schwenk M.H., Avram M.M. Estimation of glomerular filtration rate to prevent life-threatening hyperkalemia due to combined therapy with spironolactone and angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Am J Cardiol 2002, 90(6):662-663.
52. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30(5):418-424.
53. Edwards N.C., Steeds R.P., Chue C.D., Stewart P.M., Ferro C.J., Townend J.N. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharmacol 2012, 73(3):447-454.
54. Bolignano D., Palmer S.C., Navaneethan S.D., Strippoli G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014, 4:CD007004.
55. Gross E., Rothstein M., Dombek S., Juknis H.I. Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients. Am J Kidney Dis 2005, 46(1):94-101.
56. Shavit L., Neykin D., Lifschitz M., Slotki I. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study. Clin Nephrol 2011, 76(5):388-395.
57. Vardeny O., Wu D.H., Desai A., et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 2012, 60(20):2082-2089.
58. Edwards N.C., Steeds R.P., Stewart P.M., Ferro C.J., Townend J.N. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 2009, 54(6):505-512.
59. Sato A., Funder J.W., Saruta T. Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens 1999, 12(9 Pt 1):867-873.
60. Steigerwalt S., Zafar A., Mesiha N., Gardin J., Provenzano R. Role of aldosterone in left ventricular hypertrophy among African-American patients with end-stage renal disease on hemodialysis. Am J Nephrol 2007, 27(2):159-163.
61. Taheri S., Mortazavi M., Shahidi S., et al. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl 2009, 20(3):392-397.
62. Taheri S., Mortazavi M., Pourmoghadas A., Seyrafian S., Alipour Z., Karimi S. A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis. Saudi J Kidney Dis Transpl 2012, 23(3):507-512.
63. Fukuta H., Hayano J., Ishihara S., et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transpl 2003, 18(2):318-325.
64. Flevari P., Kalogeropoulou S., Drakou A., et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 2013, 31(6):1239-1244.
65. Nitta K., Akiba T., Nihei H. Aldosterone blockade and vascular calcification in hemodialysis patients. Am J Med 2003, 115(3):250.
66. Vukusich A., Kunstmann S., Varela C., et al. A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients. Clin J Am Soc Nephrol 2010, 5(8):1380-1387.
67. Chua D., Lo A., Lo C. Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?. Clin Cardiol 2010, 33(10):604-608.
68. Baker W.L., White W.B. Safety of mineralocorticoid receptor antagonists in patients receiving hemodialysis. Ann Pharmacother 2012, 46(6):889-894.
69. Rekhtman Y. Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease. Curr Hypertens Rev 2012, 8(4):267-275.
70. Hausmann M.J., Liel-Cohen N. Aldactone therapy in a peritoneal dialysis patient with decreased left ventricular function. Nephrol Dial Transpl 2002, 17(11):2035-2036.
71. Matsumoto Y., Kageyama S., Yakushigawa T., et al. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients. Cardiology 2009, 114(1):32-38.
72. Matsumoto Y., Mori Y., Kageyama S., et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014, 63(6):528-536.
73. Overdiek H.W., Merkus F.W. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 1987, 5(4):273-302.
74. Overdiek H.W., Merkus F.W. Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 1986, 40(5):531-536.
75. Gardiner P., Schrode K., Quinlan D., et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol 1989, 29(4):342-347.
76. Cook C.S., Berry L.M., Bible R.H., Hribar J.D., Hajdu E., Liu N.W. Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos 2003, 31(11):1448-1455.
77. Ravis W.R., Reid S., Sica D.A., Tolbert D.S. Pharmacokinetics of eplerenone after single and multiple dosing in subjects with and without renal impairment. J Clin Pharmacol 2005, 45(7):810-821.
78. Sica D.A. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 2005, 10(1):23-29.
79. Tolbert D.S., Reid S.E., Roniker B. Safety, tolerability, and pharmacokinetics of eplerenone, a selective aldosterone blocker. Pharmacotherapy 2002, 22(10):1331-1332.
80. Cavallari L.H., Fashingbauer L.A., Beitelshees A.L., et al. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 2004, 24(6):750-756.
81. Cavallari L.H., Groo V.L., Momary K.M., Fontana D., Viana M.A., Vaitkus P. Racial differences in potassium response to spironolactone in heart failure. CHF 2006, 12:200-205.
82. Flack J.M., Oparil S., Pratt J.H., et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41(7):1148-1155.
83. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341(10):709-717.
84. Vardeny O., Cavallari L.H., Claggett B., et al. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail 2013, 6(5):970-976.
85. Biolo A., Chao T., Duhaney T.A., et al. Usefulness of the aldosterone synthase gene polymorphism C-344-T to predict cardiac remodeling in African-Americans versus non-African-Americans with chronic systolic heart failure. Am J Cardiol 2007, 100(2):285-290.
86. Cavallari L.H., Groo V.L., Viana M.A., Dai Y., Patel S.R., Stamos T.D. Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure. Pharmacotherapy 2010, 30(1):1-9.